Cargando…

Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

Detalles Bibliográficos
Autores principales:	Jones, S. Christopher, Ryan, Debra L., Pratt, Valerie S.W., Niak, Ali, Brinker, Allen D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2015
Materias:	Departments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647172/ https://www.ncbi.nlm.nih.gov/pubmed/26597395 http://dx.doi.org/10.2337/diaspect.28.4.283

Ejemplares similares

Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone
por: Riswold, Kayla, et al.
Publicado: (2018)

Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release
por: Ko, Jung-Woo, et al.
Publicado: (2020)

A case report of severe adverse reaction of exenatide: Anaphylactic shock
por: Liu, Xujing, et al.
Publicado: (2022)

Exenatide modulates tumor–endothelial cell interactions in human ovarian cancer cells
por: Kosowska, Agnieszka, et al.
Publicado: (2017)

Annual Report of the Surgeon-General U. S. A.
por: Hammond, William A., et al.
Publicado: (1863)

Annual Report of the Surgeon General U. S. A.
Publicado: (1871)

Input Estimation for Extended-Release Formulations Exemplified with Exenatide
por: Trägårdh, Magnus, et al.
Publicado: (2017)

Annual Report of the Supervising Surgeon of the U. S. Marine Hospital Service
Publicado: (1874)

In the U.S. “Healthcare” Is Now Strictly a Business Term
por: Sawyer, Nick T.
Publicado: (2018)

WITHDRAWN: A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products
por: Rose, Jessica, et al.
Publicado: (2021)

Delayed Response to U-500 Regular Insulin
por: Davidson, Mayer B.
Publicado: (2018)

Exenatide extended-release; clinical trials, patient preference, and economic considerations
por: Doggrell, Sheila A
Publicado: (2013)

Extended Exenatide Administration Enhances Lipid Metabolism and Exacerbates Pancreatic Injury in Mice on a High Fat, High Carbohydrate Diet
por: Rouse, Rodney, et al.
Publicado: (2014)

U.S. Health Resources & Services Administration
por: Washko, Michelle M.
Publicado: (2022)

Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System
por: Yang, Hui, et al.
Publicado: (2022)

Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System
por: Li, Xiaotong, et al.
Publicado: (2023)

Therapeutic Inertia is a Problem for All of Us
por: Brunton, Stephen
Publicado: (2019)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017
por: Dores, Graça M., et al.
Publicado: (2019)

The frequencies and disparities of adverse childhood experiences in the U.S.
por: Giano, Zachary, et al.
Publicado: (2020)

Mortality of the U. S.
Publicado: (1872)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Does HIF-PHI increased risk of gastrointestinal hemorrhage in patients with renal anemia: a review of cases reported to the U.S. Food and drug administration adverse event reporting system
por: Zhou, Yangzhong, et al.
Publicado: (2021)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021
por: Learned, Christine, et al.
Publicado: (2022)

What the Latest Evidence Tells Us About Fat and Cardiovascular Health
por: Hayes, Joy, et al.
Publicado: (2016)

US visa problems amid COVID-19 disrupt materials research
por: Meiksin, Judy
Publicado: (2020)

Development and Implementation of a U-500 Regular Insulin Program in a Federally Qualified Health Center
por: Shaw, Kathy F., et al.
Publicado: (2017)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann, Katherine V, et al.
Publicado: (2014)

Admitted to the U. S. Navy
Publicado: (1869)

Appointed to the U. S. Navy
Publicado: (1868)

The First Report on the Administration of the Act
Publicado: (1913)

Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)
por: Hoffman, Keith B., et al.
Publicado: (2014)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis
por: Zhou, Zeyun, et al.
Publicado: (2020)

Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019
por: Wei, Shaokui, et al.
Publicado: (2021)

The next 75 years: Symposium sparks upgrade to US policy model for R&D
por: Meiksin, Judy
Publicado: (2020)

The first successful desensitization protocol in exenatide allergy: a case report
por: Yeğit, Osman Ozan, et al.
Publicado: (2023)

Aquifer systems extending far offshore on the U.S. Atlantic margin
por: Gustafson, Chloe, et al.
Publicado: (2019)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
por: Lipner, Shari R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oe126ot1522enb8av4mnoraeog